Plegridy (Peginterferon beta 1a)

Plegridy is manufactured in Japan.  The packaging is English and shipped from our pharmacy in India by courier.

 

Prescription Plegridy contains the active ingredient peginterferon beta-1a. Pegridy is used by adults with relapsing/remitting multiple sclerosis. Plegridy is a modified version of long acting interferon which helps the body protect itself against infections and diseases.

Multiple sclerosis is an illness that affects the brain and spinal cord where the body's immune system attacks the myelin which surround and protects the nerves located there. By disrupting the nerves, multiple sclerosis disrupts messages between the brain and the body, causing the symptoms associated with the disease. Plegridy is not a cure, but it stops the damage by your own immune system reducing the number of relapses thus slowing down the effects of multiple sclerosis.

The standard Plegridy dose is 125 mcg every 2 weeks at the same day every 14 days. When you begin with Plegridy, the dose may be less than 125 mcg. Each package of Plegridy contains 2 prefilled pens which is a 4 week supply. Plegridy is the only interferon used every 2 weeks.

Before injecting yourself with Plegridy, have your physician train you exactly how to use the pen. Be fully comfortable before you self-inject Plegridy. Follow the directions contained in the box and inject Plegridy under the skin using alternate sites for injection.

Buy Plegridy from InsulinHub.com for the best Plegridy cost.

Information about Plegridy (Peginterferon beta 1a)

Plegridy is a brand name for peginterferon beta-1a, a modified form of interferon beta used in the treatment of multiple sclerosis (MS). It works by modulating the immune system to reduce inflammation and prevent the destruction of nerve cells in the central nervous system, thus helping to slow the progression of MS and reduce the frequency of relapses.

Product Highlights

• Plegridy is primarily used to treat relapsing forms of multiple sclerosis (MS), particularly relapsing-remitting MS (RRMS), to reduce the frequency of MS flare-ups (relapses) and slow the progression of disability.
• While Plegridy is most commonly used for RRMS, it may be used off-label in other forms of MS under the guidance of a healthcare provider.

Key Ingredient

• Peginterferon beta-1a

Key Benefits

• Plegridy has been shown to decrease the frequency of relapses in patients with relapsing forms of MS, aiding in the prevention of symptom progression. 
• By reducing inflammation in the central nervous system, Plegridy helps to slow the progression of physical disability in people with MS.
• Plegridy is administered once every two weeks, making it easier for patients to adhere to the treatment regimen compared to therapies requiring more frequent injections.
• The PEGylation of interferon beta-1a in Plegridy helps extend its half-life, making it a more convenient option for patients who require long-term treatment.

Direction of Use

• The recommended dose for Plegridy is an initial loading dose of 63 mcg, administered once a week for the first 4 weeks, followed by a maintenance dose of 125 mcg every two weeks.
• Plegridy is injected subcutaneously, typically into the thigh, abdomen, or upper arm. Patients can be trained to self-administer the injection, although a healthcare provider may perform the first few injections.
• To minimize irritation or injury, the injection site should be rotated regularly, and injections should not be given into the same spot more than once in a row.

Safety Concerns

• Common side effects may include pain, redness, or swelling at the injection site. These reactions are generally mild and go away on their own. 
• Many patients experience flu-like symptoms after an injection, including fever, chills, and muscle aches. These symptoms generally improve within a few hours to a day. 
• Plegridy can affect liver function, so liver enzymes should be monitored regularly during treatment.
• Interferon therapies such as Plegridy may lead to mood changes, depression, or suicidal thoughts. Patients should be closely monitored for any alterations in mood or behavior. 
• Plegridy can lower white blood cell counts and platelets, increasing the risk of infections and bleeding. Routine blood tests may be needed to monitor these levels. 

Avoid Plegridy (Peginterferon beta-1a) If

• Plegridy should be avoided if you are allergic to Peginterferon beta-1a, interferon beta, or any of the other ingredients it contains. 
• If you have severe liver disease, Plegridy should be avoided because it can worsen liver function.
• Plegridy is classified as a pregnancy category C drug, which means it may cause harm to the fetus, and should be used only if the potential benefit outweighs the risks. It is also not recommended during breastfeeding.
• Plegridy should be avoided in patients with severe depression or a history of suicidal thoughts due to the potential for exacerbating these conditions.
• Caution is required in patients with heart disease or arrhythmias, as interferon treatments can sometimes worsen cardiac conditions.

This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.